# A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

> **NCT04451811** · PHASE1 · COMPLETED · sponsor: **Oppilan Pharma Ltd** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** OPL-002

## Key facts

- **NCT ID:** NCT04451811
- **Lead sponsor:** Oppilan Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2021-02-24
- **Final completion:** 2021-02-24
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04451811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04451811, "A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04451811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*